公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

摘要： This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.